EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pulmonary pharmacokinetics and lesion penetration of antimicrobials in patients with nontuberculous mycobacterial disease

Fumiya Watanabe iD, Miyako Hiramatsu, Toru Kawakami, Teruaki Oka, Hayato Nanami, Kiyomi Shimoda, Kazuhiko Hanada iD, Yuji Shiraishi, Kozo Morimoto iD

Antimicrobial Agents and Chemotherapy · 04.11.2026 · 70 (11)

DOI: 10.1128/aac.00820-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 04.11.2026. Verfasst von Fumiya Watanabe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacometrics and Pharmacokinetics, Meiji Pharmaceutical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Mycobacterium Infections, Nontuberculous, Lung, Anti-Bacterial Agents. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Research Foundation for Clinical Pharmacology, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The intrapulmonary pharmacokinetics of antimicrobial agents used to treat nontuberculous mycobacterial (NTM) pulmonary disease remains poorly characterized, limiting the optimization of dosing regimens. This study characterized the plasma and intrapulmonary pharmacokinetics of azithromycin, ethambutol, rifampicin, clofazimine, and amikacin, as well as their penetration into pulmonary lesion sites. We prospectively enrolled patients undergoing guideline-based treatment for NTM pulmonary disease who were indicated for surgical resection at a single center in Japan. Drug concentrations were measured in the plasma and lung samples and analyzed using a population pharmacokinetic model. The lung lesion site, cavity, or nodule/bronchiectatic lesion was evaluated as covariates of the lung-to-plasma partition ratios. Twenty-four patients were enrolled in the study. The estimated lung-to-plasma partition coefficients and intrapulmonary half-lives were 535-fold and 6.3 months for azithromycin, 40-fold and 2.0 months for ethambutol, 5.2-fold and 6.3 min for rifampicin, 18,800-fold and 22 years for clofazimine, 1.3-fold and 2.3 h for intravenous amikacin, and 1.3-fold and 5.0 h for inhaled amikacin, respectively. Evaluation of drug penetration into cavities and nodular/bronchiectatic lesions showed no clearly reduced concentration compared to a normal lung tissue. The intrapulmonary pharmacokinetic characteristics identified in this study provide valuable information for optimizing antimicrobial dosing regimens in the treatment of NTM pulmonary disease. Furthermore, the absence of clearly reduced drug penetration into lesion sites suggests that lesion phenotype alone may have limited value in guiding antimicrobial selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium Infections, NontuberculousLungAnti-Bacterial AgentsHumansFemaleClofazimineAmikacinMaleRifampinAgedEthambutolAzithromycinMiddle AgedNontuberculous MycobacteriaAged, 80 and overProspective Studies

Stichwörter der Autor:innen

Mycobacterium aviumnontuberculous mycobacteriapenetrationpharmacokineticspulmonary lesions

Substanzen

ClofazimineAmikacinRifampinEthambutolAzithromycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pharmacometrics and Pharmacokinetics, Meiji Pharmaceutical University, Tokyo, Japan.
  • Department of Pharmacy, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.
  • Department of Thoracic Surgery, Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.
  • Department of Thoracic Surgery, Higashi-yamato Hospital, Tokyo, Japan.
  • Department of Pathology, Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.
  • Department of Respiratory Medicine, Respiratory Disease Centre, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.

ORCID-Profile: Fumiya Watanabe, Kazuhiko Hanada, Kozo Morimoto

Förderung

  • Japan Research Foundation for Clinical Pharmacology
  • Japan Agency for Medical Research and Development

Zitieren

APA

Watanabe, F., Hiramatsu, M., Kawakami, T., Oka, T., Nanami, H., Shimoda, K., Hanada, K., Shiraishi, Y., & Morimoto, K. (2026). Pulmonary pharmacokinetics and lesion penetration of antimicrobials in patients with nontuberculous mycobacterial disease. Antimicrobial Agents and Chemotherapy, 70(11). https://doi.org/10.1128/aac.00820-26

Vancouver

Watanabe F, Hiramatsu M, Kawakami T, Oka T, Nanami H, Shimoda K, et al. Pulmonary pharmacokinetics and lesion penetration of antimicrobials in patients with nontuberculous mycobacterial disease. Antimicrobial Agents and Chemotherapy. 2026;70(11). doi:10.1128/aac.00820-26

BibTeX
@article{Watanabe2026,
  author = {Watanabe, Fumiya and Hiramatsu, Miyako and Kawakami, Toru and Oka, Teruaki and Nanami, Hayato and Shimoda, Kiyomi and Hanada, Kazuhiko and Shiraishi, Yuji and Morimoto, Kozo},
  title = {Pulmonary pharmacokinetics and lesion penetration of antimicrobials in patients with nontuberculous mycobacterial disease},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {11},
  doi = {10.1128/aac.00820-26}
}
Kostenlos starten →